2Akesson K, Kakonen SM, Josefsson PO, et al. Fracture-induced chan- ges in bone turnover: a potential confounder in the use of biochemical marke PS inosteoporosis[ J ]. J Bone Miner Metab, 2005,23 ( 1 ) : 30- 35.
3Koh JM, Kim GS, Oh B, et al. Microphthalmia-associated transcription factor polymorphis and association, IV im bone mineral density of the proximal femur in postmenopausal women [ J ]. Mol Ceils, 2007,23 (2) :246-251.
4Chaovisitsaree S, Namwongprom SN, Morakote N, et al. Comparison ostcoporosis serf assessment tool for Asian (OSTA) and standard as- sessment in menopause clinic, chiangmai [ J ]. J Med Assoc Thai, 2007,90 ( 3 ) :420-425.
5Tsangari H, Findlay DM, Fazzalari NL, et al. Structural and remode- ling indices in the cancellous bone of the proximal femur across adult- hood [ J ]. Bone,2007,40 ( 1 ) :211-217.
6Masi L, Ottanelli S, Berni R, et al. CYP19 and ESR1 gene polymorphisms: response of the bone mineral density in post- menopausal women to hormonal replacement therapy. Clin Cases Miner Bone Metab,2014,11 ( 1 ) :36-43.
7Gambacciani M, Levancini M. Management of postmenopausal osteoporosis and the prevention of fractures. Panminerva Med, 2014,56(2) :115-131.
8Naess6n S, Bergstr~m I, Ljungman P, et al. Long-term follow-up of bone density, general and reproductive health in female survivors after treatment for haematological malignancies. Eur J Haematol,2014,93 (2) : 137-142.
9Gupta B, Mittal P, Khuteta R, et al. A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause. J Obstet Gynaecol India,2013,63 ( 3 ) : 194-198.
10Nanes MS, Kallen CB. Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. Fertil Steril, 2009,92 ( 2 ) :403-412.
